Hyperoxaluria: A gut-kidney axis

Kidney International

Volumn 80, Issue 11, 2011, Pages 1146-1158

  Robijn, Stef ^a   Hoppe, Bernd ^b   Vervaet, Benjamin A ^a   D'Haese, Patrick C ^a   Verhulst, Anja ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CITRIC ACID; GLYOXYLIC ACID; OXALIC ACID; PROTEIN SLC26A1; PROTEIN SLC26A2; PROTEIN SLC26A3; PROTEIN SLC26A6; PROTEIN SLC26A7; PROTEIN SLC26A8; PROTEIN SLC26A9; PYRIDOXINE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD LEVEL; DIET RESTRICTION; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME METABOLISM; GASTROINTESTINAL ABSORPTION; GENETIC VARIABILITY; GLOMERULUS FILTRATION RATE; HUMAN; HYPEROXALURIA; INTESTINE ABSORPTION; INTESTINE FUNCTION; INTESTINE TRANSIT TIME; ION TRANSPORT; KIDNEY CALCIFICATION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; KIDNEY TUBULE ABSORPTION; KIDNEY TUBULE EXCRETION; NEPHROLITHIASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STOMACH EMPTYING; TRANSAMINATION; URINARY EXCRETION; URINE LEVEL;

EID: 81155150033     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.287     Document Type: Review

References (175)

1. Streit J, Tran-Ho L, Kö nigsberger E. Solubility of the three calcium oxalate hydrates in sodium chloride solutions and urine-like liquors. Monatsh Chem Chem Mon 1998; 129: 1225-1236. (Pubitemid 128353302)
2. Knight TF, Sansom SC, Senekjian HO et al. Oxalate secretion in the rat proximal tubule. Am J Physiol 1981; 240: F295-F298.
3. Senekjian HO, Weinman EJ. Oxalate transport by proximal tubule of the rabbit kidney. Am J Physiol 1982; 243: F271-F275. (Pubitemid 12037815)
4. Weinman EJ, Frankfurt SJ, Ince A et al. Renal tubular transport of organic acids. Studies with oxalate and para-aminohippurate in the rat. J Clin Invest 1978; 61: 801-806.
5. Asplin JR. Hyperoxaluric calcium nephrolithiasis. Endocrinol Metab Clin North Am 2002; 31: 927-949. (Pubitemid 35403491)
6. Verhulst A, De Broe ME. Oxalate chap 32. In: De Broe ME, Porter GA (eds). Clinical Nephrotoxins: Renal Injury from Drugs and Chemicals, 3 edn. Springer: New York, NY, USA, 2008, pp 749-756.
7. Vervaet BA, Verhulst A, Dauwe SE et al. An active renal crystal clearing mechanism in rat and man. Kidney Int 2009; 75: 41-51.
8. Lieske JC, Spargo BH, Toback FG. Endocytosis of calcium oxalate crystals and proliferation of renal tubular epithelial cells in a patient with type 1 primary hyperoxaluria. J Urol 1992; 148: 1517-1519.
9. Khan SR. Calcium oxalate crystal interaction with renal tubular epithelium, mechanism of crystal adhesion and its impact on stone development. Urol Res 1995; 23: 71-79.
10. Khan SR, Shevock PN, Hackett RL. Acute hyperoxaluria, renal injury and calcium oxalate urolithiasis. J Urol 1992; 147: 226-230.
11. Umekawa T, Chegini N, Khan SR. Oxalate ions and calcium oxalate crystals stimulate MCP-1 expression by renal epithelial cells. Kidney Int 2002; 61: 105-112. (Pubitemid 34075136)
12. Schepers MS, van Ballegooijen ES, Bangma CH et al. Crystals cause acute necrotic cell death in renal proximal tubule cells, but not in collecting tubule cells. Kidney Int 2005; 68: 1543-1553. (Pubitemid 43169899)
13. de Water R, Boeve ER, van Miert PP et al. Pathological and immunocytochemical changes in chronic calcium oxalate nephrolithiasis in the rat. Scanning Microsc 1996; 10: 577-587.
14. de Water R, Noordermeer C, van der Kwast TH et al. Calcium oxalate nephrolithiasis: effect of renal crystal deposition on the cellular composition of the renal interstitium. Am J Kidney Dis 1999; 33: 761-771. (Pubitemid 29159945)
15. Worcester EM, Parks JH, Evan AP et al. Renal function in patients with nephrolithiasis. J Urol 2006; 176: 600-603. (Pubitemid 43927885)
16. Rule AD, Bergstralh EJ, Melton LJ et al. Kidney stones and the risk for chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 804-811.
17. Hoppe B, Beck BB, Milliner DS. The primary hyperoxalurias. Kidney Int 2009; 75: 1264-1271.
18. Vervaet BA, Verhulst A, D'Haese PC et al. Nephrocalcinosis: new insights into mechanisms and consequences. Nephrol Dial Transplant 2009; 24: 2030-2035.
19. Asplin JR, Parks JH, Coe FL. Dependence of upper limit of metastability on supersaturation in nephrolithiasis. Kidney Int 1997; 52: 1602-1608. (Pubitemid 28032064)
20. Finlayson B, Reid F. The expectation of free and fixed particles in urinary stone disease. Invest Urol 1978; 15: 442-448. (Pubitemid 8347910)
21. Kok DJ, Khan SR. Calcium oxalate nephrolithiasis, a free or fixed particle disease. Kidney Int 1994; 46: 847-854. (Pubitemid 24272044)
22. Kok DJ. Crystallization and stone formation inside the nephron. Scanning Microsc 1996; 10: 471-484.
23. Verhulst A, Asselman M, Persy VP et al. Crystal retention capacity of cells in the human nephron: involvement of CD44 and its ligands hyaluronic acid and osteopontin in the transition of a crystal binding-into a nonadherent epithelium. J Am Soc Nephrol 2003; 14: 107-115. (Pubitemid 36026302)
24. Verkoelen CF, Verhulst A. Proposed mechanisms in renal tubular crystal retention. Kidney Int 2007; 72: 13-18. (Pubitemid 47014450)
25. Vervaet BA, Verhulst A, De Broe ME et al. The tubular epithelium in the initiation and course of intratubular nephrocalcinosis. Urol Res 2010; 38: 249-256.
26. Evan AP. Physiopathology and etiology of stone formation in the kidney and the urinary tract. Pediatr Nephrol 2010; 25: 831-841.
27. Tsujihata M. Mechanism of calcium oxalate renal stone formation and renal tubular cell injury. Int J Urol 2008; 15: 115-120. (Pubitemid 351207313)
28. Borghi L, Nouvenne A, Meschi T. Probiotics and dietary manipulations in calcium oxalate nephrolithiasis: two sides of the same coin? Kidney Int 2010; 78: 1063-1065.
29. Holmes RP, Goodman HO, Assimos DG. Contribution of dietary oxalate to urinary oxalate excretion. Kidney Int 2001; 59: 270-276. (Pubitemid 32055235)
30. Holmes RP, Assimos DG. The impact of dietary oxalate on kidney stone formation. Urol Res 2004; 32: 311-316. (Pubitemid 39517953)
31. Holmes RP, Ambrosius WT, Assimos DG. Dietary oxalate loads and renal oxalate handling. J Urol 2005; 174: 943-947. (Pubitemid 41140641)
32. Farinelli MP, Richardson KE. Oxalate synthesis from [14C1]glycollate and [14C1]glyoxylate in the hepatectomized rat. Biochim Biophys Acta 1983; 757: 8-14.
33. Holmes RP, Assimos DG. Glyoxylate synthesis, and its modulation and influence on oxalate synthesis. J Urol 1998; 160: 1617-1624. (Pubitemid 128746725)
34. Knight J, Assimos DG, Callahan MF et al. Metabolism of primed, constant infusions of [1,2-(13)C(2)] glycine and [1-(13)C(1)] phenylalanine to urinary oxalate. Metabolism 2010; 60: 950-956.
35. Coulter-Mackie MB. 4-Hydroxyproline metabolism and glyoxylate production: a target for substrate depletion in primary hyperoxaluria? Kidney Int 2006; 70: 1891-1893. (Pubitemid 44863374)
36. Knight J, Jiang J, Assimos DG et al. Hydroxyproline ingestion and urinary oxalate and glycolate excretion. Kidney Int 2006; 70: 1929-1934. (Pubitemid 44863380)
37. Neuman RE, Logan MA. The determination of hydroxyproline. J Biol Chem 1950; 184: 299-306.
38. Takayama T, Fujita K, Suzuki K et al. Control of oxalate formation from L-hydroxyproline in liver mitochondria. J Am Soc Nephrol 2003; 14: 939-946. (Pubitemid 36361998)
39. Marengo SR, Romani AM. Oxalate in renal stone disease: the terminal metabolite that just won't go away. Nat Clin Pract Nephrol 2008; 4: 368-377. (Pubitemid 351913707)
40. Taylor EN, Curhan GC. Fructose consumption and the risk of kidney stones. Kidney Int 2008; 73: 207-212.
41. Nguyen NU, Dumoulin G, Henriet MT et al. Increase in urinary calcium and oxalate after fructose infusion. Horm Metab Res 1995; 27: 155-158.
42. Nguyen NU, Dumoulin G, Wolf JP et al. Urinary calcium and oxalate excretion during oral fructose or glucose load in man. Horm Metab Res 1989; 21: 96-99. (Pubitemid 19091189)
43. Knight J, Assimos DG, Easter L et al. Metabolism of fructose to oxalate and glycolate. Horm Metab Res 2010; 42: 868-873.
44. Chai W, Liebman M, Kynast-Gales S et al. Oxalate absorption and endogenous oxalate synthesis from ascorbate in calcium oxalate stone formers and non-stone formers. Am J Kidney Dis 2004; 44: 1060-1069. (Pubitemid 39556486)
45. Massey LK, Liebman M, Kynast-Gales SA. Ascorbate increases human oxaluria and kidney stone risk. J Nutr 2005; 135: 1673-1677. (Pubitemid 40980717)
46. Taylor EN, Stampfer MJ, Curhan GC. Dietary factors and the risk of incident kidney stones in men: new insights after 14 years of follow-up. J Am Soc Nephrol 2004; 15: 3225-3232. (Pubitemid 39578855)
47. Auer BL, Auer D, Rodgers AL. The effect of ascorbic acid ingestion on the biochemical and physicochemical risk factors associated with calcium oxalate kidney stone formation. Clin Chem Lab Med 1998; 36: 143-147. (Pubitemid 28185322)
48. Hatch M, Mulgrew S, Bourke E et al. Effect of megadoses of ascorbic acid on serum and urinary oxalate. Eur Urol 1980; 6: 166-169. (Pubitemid 10102968)
49. Auer BL, Auer D, Rodgers AL. Relative hyperoxaluria, crystalluria and haematuria after megadose ingestion of vitamin C. Eur J Clin Invest 1998; 28: 695-700. (Pubitemid 28432120)
50. Ladwig PM, Liedtke RR, Larson TS et al. Sensitive spectrophotometric assay for plasma oxalate. Clin Chem 2005; 51: 2377-2380. (Pubitemid 41692589)
51. Lemann Jr J, Hornick LJ, Pleuss JA et al. Oxalate is overestimated in alkaline urines collected during administration of bicarbonate with no specimen pH adjustment. Clin Chem 1989; 35: 2107-2110. (Pubitemid 19262636)
52. Conyers RA, Bais R, Rofe AM. The relation of clinical catastrophes, endogenous oxalate production, and urolithiasis. Clin Chem 1990; 36: 1717-1730.
53. Gambardella RL, Richardson KE. The pathways of oxalate formation from phenylalanine, tyrosine, tryptophan and ascorbic acid in the rat. Biochim Biophys Acta 1977; 499: 156-168. (Pubitemid 8157567)
54. Milliner DS, Wilson DM, Smith LH. Phenotypic expression of primary hyperoxaluria: comparative features of types I and II. Kidney Int 2001; 59: 31-36. (Pubitemid 32055211)
55. Bobrowski AE, Langman CB. The primary hyperoxalurias. Semin Nephrol 2008; 28: 152-162. (Pubitemid 351410444)
56. Leumann E, Hoppe B. The primary hyperoxalurias. J Am Soc Nephrol 2001; 12: 1986-1993. (Pubitemid 32801376)
57. Monico CG, Persson M, Ford GC et al. Potential mechanisms of marked hyperoxaluria not due to primary hyperoxaluria I or II. Kidney Int 2002; 62: 392-400. (Pubitemid 34779750)
58. Monico CG, Weinstein A, Jiang Z et al. Phenotypic and functional analysis of human SLC26A6 variants in patients with familial hyperoxaluria and calcium oxalate nephrolithiasis. Am J Kidney Dis 2008; 52: 1096-1103.
59. Belostotsky R, Seboun E, Idelson GH et al. Mutations in DHDPSL are responsible for primary hyperoxaluria type III. Am J Hum Genet 2010; 87: 392-399.
60. Holmes RP, Kennedy M. Estimation of the oxalate content of foods and daily oxalate intake. Kidney Int 2000; 57: 1662-1667. (Pubitemid 30207924)
61. Hoppe B, von Unruh GE, Laube N et al. Oxalate degrading bacteria: new treatment option for patients with primary and secondary hyperoxaluria? Urol Res 2005; 33: 372-375. (Pubitemid 41752059)
62. Siener R, Ebert D, Nicolay C et al. Dietary risk factors for hyperoxaluria in calcium oxalate stone formers. Kidney Int 2003; 63: 1037-1043. (Pubitemid 36315582)
63. Singh PP, Kothari LK, Sharma DC et al. Nutritional value of foods in relation to their oxalic acid content. Am J Clin Nutr 1972; 25: 1147-1152.
64. von Unruh GE, Voss S, Sauerbruch T et al. Dependence of oxalate absorption on the daily calcium intake. J Am Soc Nephrol 2004; 15: 1567-1573. (Pubitemid 38679681)
65. Liebman M, Chai W. Effect of dietary calcium on urinary oxalate excretion after oxalate loads. Am J Clin Nutr 1997; 65: 1453-1459. (Pubitemid 27187757)
66. Liebman M, Costa G. Effects of calcium and magnesium on urinary oxalate excretion after oxalate loads. J Urol 2000; 163: 1565-1569. (Pubitemid 30226328)
67. Borghi L, Schianchi T, Meschi T et al. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 2002; 346: 77-84. (Pubitemid 34438897)
68. Hess B, Jost C, Zipperle L et al. High-calcium intake abolishes hyperoxaluria and reduces urinary crystallization during a 20-fold normal oxalate load in humans. Nephrol Dial Transplant 1998; 13: 2241-2247. (Pubitemid 28416547)
69. Lemann Jr J, Pleuss JA, Worcester EM et al. Urinary oxalate excretion increases with body size and decreases with increasing dietary calcium intake among healthy adults. Kidney Int 1996; 49: 200-208. (Pubitemid 26022840)
70. Hesse A, Schneeberger W, Engfeld S et al. Intestinal hyperabsorption of oxalate in calcium oxalate stone formers: application of a new test with [13C2]oxalate. J Am Soc Nephrol 1999; 10(Suppl 14): S329-S333. (Pubitemid 29498574)
71. Sikora P, von Unruh GE, Beck B et al. [13C2]oxalate absorption in children with idiopathic calcium oxalate urolithiasis or primary hyperoxaluria. Kidney Int 2008; 73: 1181-1186. (Pubitemid 351620437)
72. von Unruh GE, Langer MA, Paar DW et al. Mass spectrometric-selected ion monitoring assay for an oxalate absorption test applying [13C2]oxalate. J Chromatogr B Biomed Sci Appl 1998; 716: 343-349. (Pubitemid 28464580)
73. von Unruh GE, Voss S, Sauerbruch T et al. Reference range for gastrointestinal oxalate absorption measured with a standardized [13C2]oxalate absorption test. J Urol 2003; 169: 687-690. (Pubitemid 36133023)
74. Voss S, Hesse A, Zimmermann DJ et al. Intestinal oxalate absorption is higher in idiopathic calcium oxalate stone formers than in healthy controls: measurements with the [(13)C2]oxalate absorption test. J Urol 2006; 175: 1711-1715.
75. Zimmermann DJ, Hesse A, von Unruh GE. Influence of a high-oxalate diet on intestinal oxalate absorption. World J Urol 2005; 23: 324-329. (Pubitemid 43118488)
76. Krishnamurthy MS, Hruska KA, Chandhoke PS. The urinary response to an oral oxalate load in recurrent calcium stone formers. J Urol 2003; 169: 2030-2033. (Pubitemid 36576710)
77. Lindsjo M, Danielson BG, Fellstrom B et al. Intestinal oxalate and calcium absorption in recurrent renal stone formers and healthy subjects. Scand J Urol Nephrol 1989; 23: 55-59. (Pubitemid 19054556)
78. Williams HE, Wandzilak TR. Oxalate synthesis, transport and the hyperoxaluric syndromes. J Urol 1989; 141: 742-749.
79. Taylor EN, Curhan GC. Determinants of 24-h urinary oxalate excretion. Clin J Am Soc Nephrol 2008; 3: 1453-1460.
80. Knight J, Holmes RP, Assimos DG. Intestinal and renal handling of oxalate loads in normal individuals and stone formers. Urol Res 2007; 35: 111-117. (Pubitemid 46828948)
81. Worcester EM. Stones from bowel disease. Endocrinol Metab Clin North Am 2002; 31: 979-999. (Pubitemid 35403493)
82. Asplin JR, Coe FL. Hyperoxaluria in kidney stone formers treated with modern bariatric surgery. J Urol 2007; 177: 565-569. (Pubitemid 46054037)
83. Nelson WK, Houghton SG, Milliner DS et al. Enteric hyperoxaluria, nephrolithiasis, and oxalate nephropathy: potentially serious and unappreciated complications of Roux-en-Y gastric bypass. Surg Obes Relat Dis 2005; 1: 481-485.
84. Nasr SH, D'Agati VD, Said SM et al. Oxalate nephropathy complicating Roux-en-Y Gastric Bypass: an underrecognized cause of irreversible renal failure. Clin J Am Soc Nephrol 2008; 3: 1676-1683.
85. Lieske JC, Kumar R, Collazo-Clavell ML. Nephrolithiasis after bariatric surgery for obesity. Semin Nephrol 2008; 28: 163-173. (Pubitemid 351400303)
86. Sinha MK, Collazo-Clavell ML, Rule A et al. Hyperoxaluric nephrolithiasis is a complication of Roux-en-Y gastric bypass surgery. Kidney Int 2007; 72: 100-107. (Pubitemid 47014438)
87. Ferraz RR, Tiselius HG, Heilberg IP. Fat malabsorption induced by gastrointestinal lipase inhibitor leads to an increase in urinary oxalate excretion. Kidney Int 2004; 66: 676-682. (Pubitemid 38982011)
88. Sarica K, Akarsu E, Erturhan S et al. Evaluation of urinary oxalate levels in patients receiving gastrointestinal lipase inhibitor. Obesity (Silver Spring) 2008; 16: 1579-1584. (Pubitemid 351915115)
89. Siva S, Barrack ER, Reddy GP et al. A critical analysis of the role of gut Oxalobacter formigenes in oxalate stone disease. BJU Int 2008; 103: 18-21.
90. Mittal RD, Kumar R. Gut-inhabiting bacterium Oxalobacter formigenes: role in calcium oxalate urolithiasis. J Endourol 2004; 18: 418-424. (Pubitemid 38879129)
91. Hoppe B, Beck B, Gatter N et al. Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1. Kidney Int 2006; 70: 1305-1311. (Pubitemid 44435182)
92. Kaufman DW, Kelly JP, Curhan GC et al. Oxalobacter formigenes may reduce the risk of calcium oxalate kidney stones. J Am Soc Nephrol 2008; 19: 1197-1203.
93. Sidhu H, Schmidt ME, Cornelius JG et al. Direct correlation between hyperoxaluria/oxalate stone disease and the absence of the gastrointestinal tract-dwelling bacterium Oxalobacter formigenes: possible prevention by gut recolonization or enzyme replacement therapy. J Am Soc Nephrol 1999; 10(Suppl 14): S334-S340. (Pubitemid 29498575)
94. Sidhu H, Allison MJ, Chow JM et al. Rapid reversal of hyperoxaluria in a rat model after probiotic administration of Oxalobacter formigenes. J Urol 2001; 166: 1487-1491. (Pubitemid 32862225)
95. Hatch M, Cornelius J, Allison M et al. Oxalobacter sp. reduces urinary oxalate excretion by promoting enteric oxalate secretion. Kidney Int 2006; 69: 691-698. (Pubitemid 43237638)
96. Freel RW, Hatch M, Green M et al. Ileal oxalate absorption and urinary oxalate excretion are enhanced in Slc26a6 null mice. Am J Physiol Gastrointest Liver Physiol 2006; 290: G719-G728.
97. Jiang Z, Asplin JR, Evan AP et al. Calcium oxalate urolithiasis in mice lacking anion transporter Slc26a6. Nat Genet 2006; 38: 474-478.
98. Clark JS, Vandorpe DH, Chernova MN et al. Species differences in Cl-affinity and in electrogenicity of SLC26A6-mediated oxalate/Clexchange correlate with the distinct human and mouse susceptibilities to nephrolithiasis. J Physiol 2008; 586: 1291-1306. (Pubitemid 351321269)
99. Worcester EM, Nakagawa Y, Bushinsky DA et al. Evidence that serum calcium oxalate supersaturation is a consequence of oxalate retention in patients with chronic renal failure. J Clin Invest 1986; 77: 1888-1896. (Pubitemid 16062644)
100. Constable AR, Joekes AM, Kasidas GP et al. Plasma level and renal clearance of oxalate in normal subjects and in patients with primary hyperoxaluria or chronic renal failure or both. Clin Sci (Lond) 1979; 56: 299-304. (Pubitemid 10094401)
101. Hoppe B, Kemper MJ, Bokenkamp A et al. Plasma calcium oxalate supersaturation in children with primary hyperoxaluria and end-stage renal failure. Kidney Int 1999; 56: 268-274. (Pubitemid 29300544)
102. Costello JF, Sadovnic MJ, Cottington EM. Plasma oxalate levels rise in hemodialysis patients despite increased oxalate removal. J Am Soc Nephrol 1991; 1: 1289-1298.
103. Worcester EM, Fellner SK, Nakagawa Y et al. Effect of renal transplantation on serum oxalate and urinary oxalate excretion. Nephron 1994; 67: 414-418. (Pubitemid 24219862)
104. Pinheiro HS, Camara NO, Osaki KS et al. Early presence of calcium oxalate deposition in kidney graft biopsies is associated with poor long-term graft survival. Am J Transplant 2005; 5: 323-329. (Pubitemid 40179519)
105. Bagnasco SM, Mohammed BS, Mani H et al. Oxalate deposits in biopsies from native and transplanted kidneys, and impact on graft function. Nephrol Dial Transplant 2009; 24: 1319-1325.
106. Dorwart MR, Shcheynikov N, Yang D et al. The solute carrier 26 family of proteins in epithelial ion transport. Physiology (Bethesda) 2008; 23: 104-114.
107. Mount DB, Romero MF. The SLC26 gene family of multifunctional anion exchangers. Pflugers Arch 2004; 447: 710-721. (Pubitemid 38241456)
108. Sindic A, Chang MH, Mount DB et al. Renal physiology of SLC26 anion exchangers. Curr Opin Nephrol Hypertens 2007; 16: 484-490. (Pubitemid 47254701)
109. Soleimani M, Xu J. SLC26 chloride/base exchangers in the kidney in health and disease. Semin Nephrol 2006; 26: 375-385. (Pubitemid 44634902)
110. Brzica H, Breljak D, Krick W et al. The liver and kidney expression of sulfate anion transporter sat-1 in rats exhibits male-dominant gender differences. Pflugers Arch 2008; 457: 1381-1392.
111. Krick W, Schnedler N, Burckhardt G et al. Ability of sat-1 to transport sulfate, bicarbonate, or oxalate under physiological conditions. Am J Physiol Renal Physiol 2009; 297: F145-F154.
112. Stieger B. Regulation of the expression of the hepatocellular sulfate-oxalate exchanger SAT-1 (SLC26A1) by glyoxylate: a metabolic link between liver and kidney? J Hepatol 2011; 54: 406-407.
113. Karniski LP, Lotscher M, Fucentese M et al. Immunolocalization of sat-1 sulfate/oxalate/bicarbonate anion exchanger in the rat kidney. Am J Physiol 1998; 275: F79-F87.
114. Hatch M, Freel RW. Intestinal transport of an obdurate anion: oxalate. Urol Res 2005; 33: 1-16. (Pubitemid 40487187)
115. Regeer RR, Lee A, Markovich D. Characterization of the human sulfate anion transporter (hsat-1) protein and gene (SAT1; SLC26A1). DNA Cell Biol 2003; 22: 107-117. (Pubitemid 36408140)
116. Schnedler N, Burckhardt G, Burckhardt BC. Glyoxylate is a substrate of the sulfate-oxalate exchanger, sat-1, and increases its expression in HepG2 cells. J Hepatol 2011; 54: 513-520.
117. Heneghan JF, Akhavein A, Salas M et al. Regulated transport of sulfate and oxalate by SLC26A2/DTDST. Am J Physiol Cell Physiol 2010; 298: C1363-C1375.
118. Hatch M, Freel RW. The roles and mechanisms of intestinal oxalate transport in oxalate homeostasis. Semin Nephrol 2008; 28: 143-151. (Pubitemid 351400302)
119. Jiang Z, Grichtchenko II, Boron WF et al. Specificity of anion exchange mediated by mouse Slc26a6. J Biol Chem 2002; 277: 33963-33967.
120. Xie Q, Welch R, Mercado A et al. Molecular characterization of the murine Slc26a6 anion exchanger: functional comparison with Slc26a1. Am J Physiol Renal Physiol 2002; 283: F826-F838. (Pubitemid 35033971)
121. Lohi H, Lamprecht G, Markovich D et al. Isoforms of SLC26A6 mediate anion transport and have functional PDZ interaction domains. Am J Physiol Cell Physiol 2003; 284: C769-C779. (Pubitemid 36237529)
122. Freel RW, Morozumi M, Hatch M. Parsing apical oxalate exchange in Caco-2BBe1 monolayers: siRNA knockdown of SLC26A6 reveals the role and properties of PAT-1. Am J Physiol Gastrointest Liver Physiol 2009; 297: G918-G929.
123. Petrovic S, Barone S, Xu J et al. SLC26A7: a basolateral Cl-/HCO3-exchanger specific to intercalated cells of the outer medullary collecting duct. Am J Physiol Renal Physiol 2004; 286: F161-F169. (Pubitemid 38045054)
124. Dudas PL, Mentone S, Greineder CF et al. Immunolocalization of anion transporter Slc26a7 in mouse kidney. Am J Physiol Renal Physiol 2006; 290: F937-F945. (Pubitemid 43738983)
125. Lohi H, Kujala M, Makela S et al. Functional characterization of three novel tissue-specific anion exchangers SLC26A7,-A8, and-A9. J Biol Chem 2002; 277: 14246-14254. (Pubitemid 34968039)
126. Kim KH, Shcheynikov N, Wang Y et al. SLC26A7 is a Cl-channel regulated by intracellular pH. J Biol Chem 2005; 280: 6463-6470.
127. Kujala M, Tienari J, Lohi H et al. SLC26A6 and SLC26A7 anion exchangers have a distinct distribution in human kidney. Nephron Exp Nephrol 2005; 101: e50-e58. (Pubitemid 41208901)
128. Petrovic S, Ju X, Barone S et al. Identification of a basolateral Cl-/HCO3-exchanger specific to gastric parietal cells. Am J Physiol Gastrointest Liver Physiol 2003; 284: G1093-G1103. (Pubitemid 36597353)
129. Romero MF, Fulton CM, Boron WF. The SLC4 family of HCO 3-transporters. Pflugers Arch 2004; 447: 495-509.
130. Jennings ML, Adame MF. Characterization of oxalate transport by the human erythrocyte band 3 protein. J Gen Physiol 1996; 107: 145-159. (Pubitemid 26028786)
131. Oehlschlager S, Fuessel S, Meye A et al. Importance of erythrocyte band III anion transporter (SLC4A1) on oxalate clearance of calcium oxalate monohydrate stone-formering patients vs. normal controls. Urology 2011; 77: 250.e1.
132. Gambaro G, Marchini F, Piccoli A et al. The abnormal red-cell oxalate transport is a risk factor for idiopathic calcium nephrolithiasis: a prospective study. J Am Soc Nephrol 1996; 7: 608-612. (Pubitemid 126427127)
133. Osswald H, Hautmann R. Renal elimination kinetics and plasma half-life of oxalate in man. Urol Int 1979; 34: 440-450. (Pubitemid 10193134)
134. Chandhoke PS, Fan J. Transport of oxalate across the rabbit papillary surface epithelium. J Urol 2000; 164: 1724-1728.
135. Evan AP, Coe FL, Lingeman JE et al. Mechanism of formation of human calcium oxalate renal stones on Randall's plaque. Anat Rec (Hoboken) 2007; 290: 1315-1323. (Pubitemid 47573203)
136. Aronson PS. Essential roles of CFEX-mediated Cl(-)-oxalate exchange in proximal tubule NaCl transport and prevention of urolithiasis. Kidney Int 2006; 70: 1207-1213. (Pubitemid 44435171)
137. Chapman JM, Karniski LP. Protein localization of SLC26A2 (DTDST) in rat kidney. Histochem Cell Biol 2010; 133: 541-547.
138. Wang T, Agulian SK, Giebisch G et al. Effects of formate and oxalate on chloride absorption in rat distal tubule. Am J Physiol 1993; 264: F730-F736. (Pubitemid 23118153)
139. Ko SB, Zeng W, Dorwart MR et al. Gating of CFTR by the STAS domain of SLC26 transporters. Nat Cell Biol 2004; 6: 343-350. (Pubitemid 38584824)
140. Hoppe B, von Unruh GE, Blank G et al. Absorptive hyperoxaluria leads to an increased risk for urolithiasis or nephrocalcinosis in cystic fibrosis. Am J Kidney Dis 2005; 46: 440-445. (Pubitemid 41208179)
141. Terribile M, Capuano M, Cangiano G et al. Factors increasing the risk for stone formation in adult patients with cystic fibrosis. Nephrol Dial Transplant 2006; 21: 1870-1875. (Pubitemid 43985715)
142. Bergsland KJ, Zisman AL, Asplin JR et al. Evidence for net renal tubule oxalate secretion in patients with calcium kidney stones. Am J Physiol Renal Physiol 2011; 300: F311-F318.
143. Kasidas GP, Nemat S, Rose GA. Plasma oxalate and creatinine and oxalate/creatinine clearance ratios in normal subjects and in primary hyperoxaluria. Evidence for renal hyperoxaluria. Clin Chim Acta 1990; 191: 67-77.
144. Dawson PA, Russell CS, Lee S et al. Urolithiasis and hepatotoxicity are linked to the anion transporter Sat1 in mice. J Clin Invest 2010; 120: 706-712.
145. Hautmann RE. The stomach: a new and powerful oxalate absorption site in man. J Urol 1993; 149: 1401-1404. (Pubitemid 23164530)
146. Chen Z, Ye Z, Zeng L et al. Clinical investigation on gastric oxalate absorption. Chin Med J 2003; 116: 1749-1751. (Pubitemid 38008254)
147. Hatch M, Freel RW, Vaziri ND. Characteristics of the transport of oxalate and other ions across rabbit proximal colon. Pflugers Arch 1993; 423: 206-212. (Pubitemid 23137294)
148. Hatch M, Freel RW, Vaziri ND. Mechanisms of oxalate absorption and secretion across the rabbit distal colon. Pflugers Arch 1994; 426: 101-109. (Pubitemid 24034993)
149. Hatch M, Freel RW, Vaziri ND. Intestinal excretion of oxalate in chronic renal failure. J Am Soc Nephrol 1994; 5: 1339-1343. (Pubitemid 24977118)
150. Watts R, Veall N, Purkiss P. Oxalate dynamics and removal rates during haemodialysis and peritoneal dialysis in patients with primary hyperoxaluria and severe renal failure. Clin Sci (Lond) 1984; 66: 591-597. (Pubitemid 14156955)
151. Chernova MN, Jiang L, Friedman DJ et al. Functional comparison of mouse slc26a6 anion exchanger with human SLC26A6 polypeptide variants: differences in anion selectivity, regulation, and electrogenicity. J Biol Chem 2005; 280: 8564-8580. (Pubitemid 40349761)
152. Wang Z, Wang T, Petrovic S et al. Renal and intestinal transport defects in Slc26a6-null mice. Am J Physiol Cell Physiol 2005; 288: C957-C965. (Pubitemid 40395075)
153. Costello JF, Smith M, Stolarski C et al. Extrarenal clearance of oxalate increases with progression of renal failure in the rat. J Am Soc Nephrol 1992; 3: 1098-1104.
154. Hatch M, Freel RW. Angiotensin II involvement in adaptive enteric oxalate excretion in rats with chronic renal failure induced by hyperoxaluria. Urol Res 2003; 31: 426-432. (Pubitemid 38004931)
155. Hatch M, Freel RW, Vaziri ND. Regulatory aspects of oxalate secretion in enteric oxalate elimination. J Am Soc Nephrol 1999; 10(Suppl 14): S324-S328. (Pubitemid 29498573)
156. Leumann E, Hoppe B, Neuhaus T. Management of primary hyperoxaluria: efficacy of oral citrate administration. Pediatr Nephrol 1993; 7: 207-211. (Pubitemid 23093710)
157. Hamm LL. Renal handling of citrate. Kidney Int 1990; 38: 728-735. (Pubitemid 20299427)
158. Milliner DS, Eickholt JT, Bergstralh EJ et al. Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria. N Engl J Med 1994; 331: 1553-1558. (Pubitemid 24366902)
159. Monico CG, Rossetti S, Olson JB et al. Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele. Kidney Int 2005; 67: 1704-1709. (Pubitemid 40577704)
160. van Woerden CS, Groothoff JW, Wijburg FA et al. Clinical implications of mutation analysis in primary hyperoxaluria type 1. Kidney Int 2004; 66: 746-752. (Pubitemid 38982018)
161. Hoppe B, Leumann E, von Unruh G et al. Diagnostic and therapeutic approaches in patients with secondary hyperoxaluria. Front Biosci 2003; 8: e437-e443.
162. Hoppe B, Groothoff JW, Hulton SA et al. Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria. Nephrol Dial Transplant; e-pub ahead of print 2 April 2011.
163. Campieri C, Campieri M, Bertuzzi V et al. Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration. Kidney Int 2001; 60: 1097-1105. (Pubitemid 34205810)
164. Lieske JC, Goldfarb DS, De Simone C et al. Use of a probiotic to decrease enteric hyperoxaluria. Kidney Int 2005; 68: 1244-1249. (Pubitemid 43246443)
165. Lieske JC, Tremaine WJ, De Simone C et al. Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation. Kidney Int 2010; 78: 1178-1185.
166. Cowley AB, Poage DW, Dean RR et al. 14-day repeat-dose oral toxicity evaluation of oxazyme in rats and dogs. Int J Toxicol 2010; 29: 20-31.
167. Grujic D, Salido EC, Shenoy BC et al. Hyperoxaluria is reduced and nephrocalcinosis prevented with an oxalate-degrading enzyme in mice with hyperoxaluria. Am J Nephrol 2008; 29: 86-93.
168. Caravaca F, Ruiz AB, Escola JM et al. Either calcium carbonate or sevelamer decreases urinary oxalate excretion in chronic renal failure patients. Nefrologia 2007; 27: 466-471.
169. Lieske JC, Regnier C, Dillon JJ. Use of sevelamer hydrochloride as an oxalate binder. J Urol 2008; 179: 1407-1410.
170. Takahashi Y, Tanaka A, Nakamura T et al. Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int 2004; 65: 1099-1104. (Pubitemid 38251086)
171. Barmeyer C, Ye JH, Sidani S et al. Characteristics of rat downregulated in adenoma (rDRA) expressed in HEK 293 cells. Pflugers Arch 2007; 454: 441-450. (Pubitemid 46742430)
172. Knauf F, Yang CL, Thomson RB et al. Identification of a chlorideformate
173. Petrovic S, Wang Z, Ma L et al. Colocalization of the apical Cl-/HCO3-exchanger PAT1 and gastric H-K-ATPase in stomach parietal cells. Am J Physiol Gastrointest Liver Physiol 2002; 283: G1207-G1216. (Pubitemid 35192858)
174. Petrovic S, Ma L, Wang Z et al. Identification of an apical Cl-/HCO-3 exchanger in rat kidney proximal tubule. Am J Physiol Cell Physiol 2003; 285: C608-C617. (Pubitemid 37022059)
175. Corbetta S, Eller-Vainicher C, Frigerio M et al. Analysis of the 206M polymorphic variant of the SLC26A6 gene encoding a Cl-oxalate transporter in patients with primary hyperparathyroidism. Eur J Endocrinol 2009; 160: 283-288.